Innate Total Liab from 2010 to 2024
| IPHA Stock | USD 1.69 0.11 6.11% |
Total Liabilities | First Reported 2009-12-31 | Previous Quarter 122.7 M | Current Value 122.7 M | Quarterly Volatility 131.7 M |
Check Innate Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innate Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 1.1 M or Selling General Administrative of 14.6 M, as well as many indicators such as Price To Sales Ratio of 3.86, Dividend Yield of 0.0023 or PTB Ratio of 2.82. Innate financial statements analysis is a perfect complement when working with Innate Pharma Valuation or Volatility modules.
Innate | Total Liab |
Latest Innate Pharma's Total Liab Growth Pattern
Below is the plot of the Total Liab of Innate Pharma over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Innate Pharma's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Innate Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Innate Total Liab Regression Statistics
| Arithmetic Mean | 124,324,760 | |
| Geometric Mean | 77,244,613 | |
| Coefficient Of Variation | 70.43 | |
| Mean Deviation | 72,649,355 | |
| Median | 151,448,000 | |
| Standard Deviation | 87,566,111 | |
| Sample Variance | 7667.8T | |
| Range | 279.3M | |
| R-Value | 0.53 | |
| Mean Square Error | 5914.2T | |
| R-Squared | 0.28 | |
| Significance | 0.04 | |
| Slope | 10,430,788 | |
| Total Sum of Squares | 107349.5T |
Innate Total Liab History
About Innate Pharma Financial Statements
Innate Pharma stakeholders use historical fundamental indicators, such as Innate Pharma's Total Liab, to determine how well the company is positioned to perform in the future. Although Innate Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Innate Pharma's assets and liabilities are reflected in the revenues and expenses on Innate Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Innate Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 132.3 M | 106.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out the analysis of Innate Pharma Correlation against competitors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.44) | Revenue Per Share 0.419 | Quarterly Revenue Growth (0.69) | Return On Assets (0.14) |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.